Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.

Confocal imaging of antigen-induced arthritis in mouse knee. Image taken by Kristina Zec
Confocal imaging of antigen-induced arthritis in mouse knee. Image taken by Kristina Zec.

A new Oxford-Zeiss Centre of Excellence (Oxford-ZCoE) in Biomedical Imaging has opened its doors to researchers at the University of Oxford. A strategic partnership between the Kennedy Institute of Rheumatology (KIR) and the Institute of Developmental and Regenerative Medicine (IDRM), the new centre brings advanced state-of-the-art Zeiss imaging equipment and analysis tools to advance the study of global health and disease.

The first centre of its kind in the UK and Europe, Oxford-ZCoE is centred on the close relationship between the Carl Zeiss AG and Oxford. Professor Marco Fritzsche, Scientific Director of the Oxford-ZCoE said: "Our partnership with Zeiss has enabled Oxford to develop a facility providing the latest technologies in live imaging that will keep it competitive with international research."

The KIR and IRDM have broad research interests across immunology, neurology, embryology, cardiology, and cancer. Their goal is to study the key biological processes that underpin normal healthy development, and where these may go wrong in disease. Improvements in microscopy resolution and fast imaging enable researchers to observe complex functions and behaviour at the single cell level, within tissues, and across whole organisms. The Oxford-ZCoE provides a broad spectrum of different technologies that can answer research questions in living samples with a view to treating some of the world's most prolific diseases such as cancer, cardiovascular disease, neuro-degenerative diseases, or conditions related to inflammation or tissue repair.

For example, in addition to a range of recently installed lattice light sheet microscopes, the centre has introduced two of the latest fast Zeiss 980 Airyscan confocals. These state-of-the-art microscopes are the workhorses of super-resolution imaging and include super-fast scanners and spectroscopy. These sit alongside a multi-photon microscope for powerful deep imaging, and low magnification systems for imaging fixed tissues and large tile regions. All the microscopy technologies are supported by arivis AG (a Zeiss company), who provide the software for image analysis and interpretation, ensuring researchers have a complete end-to-end service.

One of the most future thinking aspects of the partnership with Zeiss is its ability to evolve the imaging facility based on the latest research questions.

"We have built a concept that not only gives our researchers access to the latest commercially available optical imaging microscopes, but also to the unique expertise of Zeiss engineers in their Research and Development team," explained Professor Fritzsche. "This gives us the freedom to raise questions relating to our areas of biological study that may challenge current microscopy capabilities, allowing us to continue to develop new technologies and transform microscopy across our research interests."

"ZEISS are delighted to have formed such an important strategic partnership with the KIR at the University of Oxford in the year of our 175th anniversary. Close collaboration with great scientific minds has been at the forefront of ZEISS' philosophy from the inception of the company in 1846 and continues to this day," said aid Dr. Ben Ewins, ZEISS account manager for Oxford University.

Read the full story on the NDORMS website. 

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.